N-(3-溴-4-甲基苯基)-4-(4-吡啶甲基)-1-酞嗪胺
|
|
- CAS号:
- 300842-64-2
- 英文名:
- N-(3-Bromo-4-methylphenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine
- 英文别名:
- Acc-789;ZK 202650;NVP-ACC-789;ACC-789 (NVP-ACC789);ACC-789; ZK-202650; NVP-ACC-789;ACC789;ACC 789;N-(3-Bromo-4-methylphenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine;N-(3-Bromo-4-methylphenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine;1-Phthalazinamine, N-(3-bromo-4-methylphenyl)-4-(4-pyridinylmethyl)-;NVP ACC789,Platelet-derived growth factor receptor,inhibit,ZK 202650,PDGFR,NVPACC789,Inhibitor,ZK-202650,ACC789,NVP-ACC789,VEGFR,ACC 789,NVP-ACC-789,Vascular endothelial growth factor receptor
- 中文名:
- N-(3-溴-4-甲基苯基)-4-(4-吡啶甲基)-1-酞嗪胺
- 中文别名:
- 化合物NVP-ACC789;N-(3-溴-4-甲基苯基)-4-(4-吡啶甲基)-1-酞嗪胺;N-(3-溴-4-甲基苯基)-4-(吡啶-4-基甲基)酞嗪-1-胺
- CBNumber:
- CB72516201
- 分子式:
- C21H17BrN4
- 分子量:
- 405.29
- MOL File:
- 300842-64-2.mol
|
|
|
N-(3-溴-4-甲基苯基)-4-(4-吡啶甲基)-1-酞嗪胺化学性质
-
沸点:
-
607.7±55.0 °C(Predicted)
-
|
-
密度:
-
1.441
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
DMSO:13.0(Max Conc. mg/mL);32.08(Max Conc. mM)
DMF:0.5(Max Conc. mg/mL);1.23(Max Conc. mM) DMF:PBS (pH 7) (1:10):0.09(Max Conc. mg/mL);0.22(Max Conc. mM) Ethanol:0.2(Max Conc. mg/mL);0.49(Max Conc. mM)-
|
-
形态:
-
A crystalline solid
-
|
-
酸度系数(pKa):
-
5.46±0.10(Predicted)
-
|
N-(3-溴-4-甲基苯基)-4-(4-吡啶甲基)-1-酞嗪胺性质、用途与生产工艺
NVP-ACC789 是 人 VEGFR-1,VEGFR-2 (鼠 VEGFR-2),VEGFR-3 和 PDGFR-β 的抑制剂,IC50 值分别为 0.38,0.02 (0.23),0.18 和 1.4 μM。
VEGFR-2
0.02 μM (IC
50
)
|
VEGFR-1
0.38 μM (IC
50
)
|
mVEGFR-2
0.23 μM (IC
50
)
|
VEGFR-3
0.18 μM (IC
50
)
|
PDGFR-β
1.4 μM (IC
50
)
|
The enzymatic kinase assays demonstrate that NVP-ACC789 is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC
50
s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively. In VEGF-treated cultures, addition of the VEGFR-2 inhibitor NVP-ACC789 reduces BME cell number to baseline levels from 1 μM. Likewise, bFGF-induced BME cell proliferation is reduced markedly by NVP-ACC789 from 1 to 10 μM, without however reaching basal levels. NVP-ACC789 is found to be a potent inhibitor of VEGF-induced HUVE cell proliferation with an IC
50
of 1.6 nM. NVP-ACC789 also completely inhibits VEGF-induced BME and BAE cell invasion and VEGF-C-induced BAE cell invasion. The inhibition is dose-dependent in both cell types with a maximal effect from 1 μM.
NVP-ACC789 which is given in daily oral doses for 6 days blocks VEGF-induced angiogenesis in a dose-dependent manner. NVP-ACC789 also inhibits the response to bFGF to some extent, but the dose-response curve is not linear for NVP-ACC789.
N-(3-溴-4-甲基苯基)-4-(4-吡啶甲基)-1-酞嗪胺
上下游产品信息
上游原料
下游产品
更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
---|
2024/01/25 | HY-19624 | NVP-ACC789 | | 1 mg | 200元 |
2024/01/25 | HY-19624 | N-(3-溴-4-甲基苯基)-4-(4-吡啶甲基)-1-酞嗪胺 NVP-ACC789 | 300842-64-2 | 5mg | 500元 |
N-(3-溴-4-甲基苯基)-4-(4-吡啶甲基)-1-酞嗪胺
生产厂家
300842-64-2, N-(3-溴-4-甲基苯基)-4-(4-吡啶甲基)-1-酞嗪胺 相关搜索:
- N-(3-溴-4-甲基苯基)-4-(吡啶-4-基甲基)酞嗪-1-胺
- 化合物NVP-ACC789
- N-(3-溴-4-甲基苯基)-4-(4-吡啶甲基)-1-酞嗪胺
- 300842-64-2
- 1-Phthalazinamine, N-(3-bromo-4-methylphenyl)-4-(4-pyridinylmethyl)-
- NVP ACC789,Platelet-derived growth factor receptor,inhibit,ZK 202650,PDGFR,NVPACC789,Inhibitor,ZK-202650,ACC789,NVP-ACC789,VEGFR,ACC 789,NVP-ACC-789,Vascular endothelial growth factor receptor
- N-(3-Bromo-4-methylphenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine
- ACC-789; ZK-202650; NVP-ACC-789;ACC789;ACC 789
- ACC-789 (NVP-ACC789)
- NVP-ACC-789
- ZK 202650
- Acc-789
- N-(3-Bromo-4-methylphenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine